Actively Recruiting
Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing
Led by Tongji Hospital · Updated on 2025-02-11
200
Participants Needed
1
Research Sites
295 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Exploring the precise medicine of patients with primary hepatobiliary cancer. And evaluate the efficacy and safety of individualized treatment regimens for primary hepatobiliary cancer based on next-generation sequencing.
CONDITIONS
Official Title
Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age from 18 to 65 years, male or female
- Diagnosis of stage IV hepatobiliary cancer confirmed by imaging and pathology
- Receiving palliative care as preferred treatment
- Genetic test shows gene mutation treatable by approved commercial drugs
- ECOG performance status between 0 and 2
- Life expectancy of 3 months or more
- Signed informed consent form
You will not qualify if you...
- Hepatobiliary cancer stage I-III or eligible for radical surgery
- Genetic test shows no gene mutation or mutation without available medicine
- ECOG performance status 3 or higher
- Pregnant female or not using birth control
- Serious cardiovascular or cerebrovascular diseases
- Abnormal liver or kidney function (e.g., jaundice, ascites, high bilirubin or alkaline phosphatase, proteinuria grade 3 or more, renal failure)
- Persistent infection grade 2 or higher
- Major surgery within 4 weeks before screening or not recovered
- Epilepsy or untreated brain metastases
- Unhealed wounds, ulcers, fractures, or history of transplantation
- Bleeding events grade 3 or higher or coagulation disorders
- Known HIV infection
- Drug abuse or unstable compliance
- Unresolved toxicity from previous treatment above grade 1 except alopecia, anemia, or hypothyroidism
- Investigator judgment against enrollment
- Participation in another clinical trial during the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hepatic Surgery Center, Tongji Hospital, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430030
Actively Recruiting
Research Team
B
Bixiang Zhang, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here